tbuckley/cabot-search huggingface dataset:
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
Authors: Anne C. Goldberg, Lawrence A. Leiter, Erik S. G. Stroes, Seth J. Baum, Jeffrey C. Hanselman, LeAnne T. Bloedon, Narendra D. Lalwani, Pragna M. Patel, Xin Zhao, P. Barton Duell
Journal: JAMA (2019)

<h3>Importance</h3> Additional treatment options are needed for patients who do not achieve sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with available lipid-lowering therapies. <h3>Objective</h3> To assess the efficacy of bempedoic acid vs placebo in patients at high cardiovascular risk receiving maximally tolerated lipid-lowering therapy. <h3>Design, Setting, and Participants</h3> Phase 3, randomized, double-blind, placebo-controlled clinical trial conducted at 91 clinical sites in North America and Europe from November 2016 to September 2018, with a final date of follow-up of September 22, 2018. A total of 779 patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both met randomization criteria, which included LDL-C level 70 mg/dL (1.8 mmol/L) or greater while receiving maximally tolerated lipid-lowering therapy. <h3>Interventions</h3> Patients were randomized 2:1 to treatment with bempedoic acid (180 mg) (n = 522) or placebo (n = 257) once daily for 52 weeks. <h3>Main Outcomes and Measures</h3> The primary end point was percent change from baseline in LDL-C level at week 12. Secondary measures included changes in levels of lipids, lipoproteins, and biomarkers. <h3>Results</h3> Among 779 randomized patients (mean age, 64.3 years; 283 women [36.3%]), 740 (95.0%) completed the trial. At baseline, mean LDL-C level was 120.4 (SD, 37.9) mg/dL. Bempedoic acid lowered LDL-C levels significantly more than placebo at week 12 (–15.1% vs 2.4%, respectively; difference, –17.4% [95% CI, –21.0% to –13.9%];<i>P</i> &lt; .001). Significant reductions with bempedoic acid vs placebo were observed at week 12 for non–high-density lipoprotein cholesterol (–10.8% vs 2.3%; difference, –13.0% [95% CI, –16.3% to –9.8%];<i>P</i> &lt; .001), total cholesterol (–9.9% vs 1.3%; difference, –11.2% [95% CI, –13.6% to –8.8%];<i>P</i> &lt; .001), apolipoprotein B (–9.3% vs 3.7%; difference, –13.0% [95% CI, –16.1% to –9.9%];<i>P</i> &lt; .001), and high-sensitivity C-reactive protein (median, –18.7% vs –9.4%; difference, –8.7% [asymptotic confidence limits, –17.2% to –0.4%];<i>P</i> = .04). Common adverse events included nasopharyngitis (5.2% vs 5.1% with bempedoic acid and placebo, respectively), urinary tract infection (5.0% vs 1.9%), and hyperuricemia (4.2% vs 1.9%). <h3>Conclusions and Relevance</h3> Among patients at high risk for cardiovascular disease receiving maximally tolerated statins, the addition of bempedoic acid compared with placebo resulted in a significant lowering of LDL-C level over 12 weeks. Further research is needed to assess the durability and clinical effect as well as long-term safety. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT02991118
Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells
Authors: Sara Rodríguez, Cirino Botta, Jon Celay, Ibai Goicoechea, Cristina Jiménez, Maria J Garcia-Barchino, Rafael Valdés-Mas, Yolanda Carrasco, Juan José Garcés, Marta Larrayoz, Susana Santos, Diego Alignani, Amaia Vilas-Zornoza, Cristina Pérez Ruiz, Sonia Garate, Sarvide Sarai, Aitziber Lopez Lopez, Christian Reinhardt, Isidro Sanchez-Garcia, Maria Jose Larrayoz, María José Calasanz, Felipe Prosper, Marina Motta, Giuseppe Rossi, Antonio Sacco, Massimo Gentile, Sara Duarte, Helena Vitoria, Catarina Geraldes, Artur Paiva, Ramón Garcia-Sanz, Aldo M. Roccaro, Jesus F. San-Miguel, Jose Angel Martinez-Climent, Bruno Paiva
Journal: Blood (2020)
Anti-CD19-CAR T-Cell from Patients Relapsed after Allo-HSCT with a Low Level of Donor Chimerism Restored to Complete Donor Chimerism: Successful Cases and Analysis
Authors: Qing Li, Juan Mu, Zhen-xing Yang, Nan Mou, Jia Wang, Ji-jun Yuan, Yanyu Jiang, Meng Juanxia, Qi Deng
Journal: Blood (2019)
First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study
Authors: Yuankai Shi, Yongping Song, Yan Qin, Qingyuan Zhang, Xiaohong Han, Xiaonan Hong, Dong Wang, Xiaofeng Zeng, Pei Hu, Shuiyu Zhao, Kaka Y. Hong, Chaoming Ma, Jiancheng Cheng, Peng Ting, Kevin Li, Weidong Jiang, Scott Liu, Eugene Liu, Xin Zhang, Katherine Chai, Dan Yao, Alvin Y. Luk
Journal: Blood (2019)
Modeling of Immune Reconstitution Post CD34 Selected Stem Cell Transplantation in Pediatric Patients with Severe Combined Immune Deficiency
Authors: Jean-Sebastien Diana, Naim Bouazza, Chloé Couzin, Martin Castelle, Alessandra Magnani, Elisa Magrin, Laure Joseph, Marianne Delville, Francois Lefrere, jean-Marc Treluyer, Capucine Picard, Despina Moshous, Isabelle André, Stephane Blanche, Benedicte Neven, Marina Cavazzana
Journal: Blood (2019)
Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece
Authors: Argiris Symeonidis, Sotirios Papageorgiou, Antonis Patrinos, Maria Melachrinou, Alexandra Kourakli, Vassiliki Pappa, Maria K. Angelopoulou, Anastasia Sioni, Nikolaos Kanellias, Sofia Chatzileontiadou, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, Maria Papaioannou, Evangelos Terpos, Gerasimos Pangalis, Theodoros P. Vassilakopoulos
Journal: Blood (2019)
Trends in Mortality for Medicare Beneficiaries Treated in the Emergency Department From 2009 to 2016
Authors: Laura G. Burke, Stephen K. Epstein, Ryan C. Burke, E. John Orav, Ashish K. Jha
Journal: JAMA Internal Medicine (2019)

Emergency department (ED) visits are common and increasing. Whether outcomes associated with care in the ED are improving over time is largely unknown to date.To examine trends in 30-day mortality rates associated with ED care among Medicare beneficiaries aged 65 years or older.This cross-sectional study used a random 5% sample in 2009 and 2010 and a 20% sample from 2011 to 2016, for a total of 15 416 385 ED visits from 2009 to 2016 among Medicare beneficiaries aged 65 years or older.Time (year) as a continuous variable.The primary outcome was 30-day mortality, overall and stratified by illness severity and hospital characteristics. Secondary outcomes included mortality rates on the day of the ED visit (day 0) as well as at 7 and 14 days. Changes in disposition from the ED (admission, observation, transfer, died in the ED, and discharged) over time were also examined.The sample included 15 416 385 ED visits (60.8% women and 39.2% men; mean [SD] age, 78.6 [8.5] years) at 4828 acute care hospitals. The percentage of patients discharged from the ED increased from 53.6% in 2009 to 56.7% in 2016. Unadjusted 30-day mortality declined from 5.1% in 2009 to 4.6% in 2016 (-0.068% per year; 95% CI, -0.074% to -0.063% per year; P < .001). After adjusting for hospital random effects, patient demographics, and chronic conditions, the adjusted 30-day mortality trend was -0.198% per year (95% CI, -0.204% to -0.193% per year; P < .001). The magnitude of this trend was greatest for patients with a high severity of illness (-0.662%; 95% CI, -0.681% to -0.644%; P < .001), followed by those with a medium severity of illness (-0.103% per year; 95% CI, -0.108% to -0.097% per year; P < .001) and those with a low severity of illness (-0.009% per year; 95% CI, -0.006% to -0.011% per year; P < .001). Declines in mortality were seen in each category of ED disposition, including visits resulting in admission (-0.356% per year; 95% CI, -0.368% to -0.343% per year; P < .001) as well as those resulting in discharge (-0.059% per year; 95% CI, -0.064% to -0.055% per year; P < .001). The decline was greater for major teaching hospitals (compared with nonteaching hospitals), nonprofit hospitals (compared with for-profit hospitals), and urban hospitals (compared with rural hospitals).Among Medicare beneficiaries receiving ED care in the United States, mortality within 30 days of an ED visit appears to have declined in recent years, particularly for patients with the highest severity of illness, even as fewer patients are being admitted from an ED visit. This study's findings suggest that further study is needed to understand the reasons for this decline and why certain types of hospitals are seeing greater improvements in outcomes.
John Pentland Alexander
Authors: John Brian Alexander
Journal: BMJ (2019)

In 1940 John Pentland Alexander and his family were evacuated from the south of England to County Fermanagh, where he attended Portora Royal School in Enniskillen. He learnt the art of fly fishing from his father, who had learnt while visiting Kashmir when stationed with the Royal Army Medical Corps before and during the second world war. At school John was a competitive oarsman, and he maintained this interest when rowing for …
Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma
Authors: Takeshi Harada, Asuka Oda, Hiroto Ohguchi, Yohann Grondin, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson, Masahiro Abe
Journal: Blood (2019)
RBTT-01. A PHASE 2 TRIAL WITH ABI-009 (NAB-SIROLIMUS) AS SINGLE-AGENT AND COMBINATIONS IN RECURRENT HIGH-GRADE GLIOMA (rHGG) AND IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM)
Authors: Santosh Kesari, Tiffany Juarez, Jose Carrillo, Judy Truong, Minhdan Nguyen, Annie Heng, Jaya Gill, Hanh Nguyen, Natsuko Nomura, Berta Grigorian, Shihe Hou, Anita Schmid, Neil Desai
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The mTOR pathway is frequently activated in patients with GBM and is associated with reduced survival, making this pathway a promising target. However, mTOR inhibitors, including everolimus and temsirolimus, have poor brain penetration, limiting their potential use for GBM. ABI-009 is a novel albumin-bound mTOR inhibitor that has a distinct PK profile and biodistribution, including CNS penetration. The goal of this prospective, multi-cohort open-label phase 2 study is to evaluate the efficacy and safety of ABI-009 monotherapy and combination therapy in rHGG and ndGBM. METHODS Eligible patients are ≥18 years old, KPS score ≥70, and have histologically confirmed rHGG or ndGBM. Arm A has 5 cohorts in patients with rHGG, naïve to mTOR inhibitors: 1) ABI-009 single agent IV 100 mg/m2; 2–5) ABI-009 60mg/m2 plus TMZ 50mg/m2 or BEV 5mg/kg or marizomib 0.8mg/m2 or CCNU 90mg/m2. In Arm B for patients with ndGBM, ABI-009 100mg/m2 is given weekly for 4 weeks (Induction) after surgery, followed by ABI-009 at 60mg/m2 plus RT/TMZ. Up to 19 patients per cohort will be enrolled: initial 9 patients with a stopping rule that only if there are ≥2 responses will the study proceed to further enrollment of the next 10 patients (Simon’s 2-stage design). Treatment will continue until disease progression or unacceptable toxicity. The primary endpoint for all cohorts is overall response rate per RANO criteria; secondary endpoints are median PFS and OS, 6-month and 12-month PFS, 12-month OS, and safety. This study is open and actively enrolling patients. The anticipated enrollment period is 24 months. NCT03463265
Sleep Disturbance Among Patients with Myelodysplastic Syndromes and Acute Leukemia
Authors: Marlise Luskin, Eric Zhou, Zilu Zhang, Daniel J. DeAngelo, Richard Stone, Martha Wadleigh, Jacqueline S Garcia, Eric S. Winer, Christopher Recklitis, Kelsey O'Day, Victoria Lapiana, Ryan Osborn, David P. Steensma, Gregory A. Abel
Journal: Blood (2019)
PDTM-19. MYC AND FAK/SRC COMBINATION TREATMENT OF FOXR2-HIGH BRAIN TUMORS
Authors: Pauline Beckmann, Ryan Krebs, Jon Larson, David Largaespada
Journal: Neuro-Oncology (2019)

Abstract Brain tumors are the leading cause of cancer-related deaths in children. To identify novel therapeutic targets in two types of pediatric brain tumors, medulloblastoma (MB) and central nervous system primitive neuroectodermal tumors (CNS-PNETs), we performed a Sleeping Beauty transposon mutagenesis screen in mice. In doing this, we identified FOXR2 (Forkhead box R2) as a candidate oncogene in MB. FOXR2 is expressed at high levels in a subset of human MB and increased FOXR2 expression drives MB formation in mice. FOXR2 has been implicated as an oncogene in several cancers of neural original, including CNS-PNET, adult and pediatric high-grade glioma, and malignant peripheral nerve sheath tumors. We have also found that FOXR2 is upregulated in non-MYCN amplified high-risk neuroblastoma. Therefore, we propose that FOXR2 represents a strong candidate for targeted therapy across multiple brain tumor entities. We have uncovered a dual role of FOXR2 in stabilization of CMYC protein and activation of the FAK/SRC signaling pathway. We are working to further define the mechanism of FOXR2-mediated MYC stabilization and FAK/SRC activation. We plan to treat FOXR2-high tumors with combinations of drugs effective against tumors with high MYC, FAK, or SRC in clinical development. Inhibitors or combinations of that score well in vitro will be used to treat mice with orthotopically injected FOXR2-high tumor cells (MB, neuroblastoma, and glioma). In addition, we are working to construct mouse models of FOXR2-driven neural tumors for use in drug testing. We hypothesize that FOXR2-high tumors will be sensitive to MYC and FAK/SRC inhibitor combination therapy, establishing FOXR2 as a molecular marker for treatment success of MYC and FAK/SRC inhibitors in patients.
Asymptomatic Infiltrated Erythematous Skin Patch on the Breast
Authors: Magda Zanelli, Maurizio Zizzo, Stefano Ascani
Journal: JAMA Dermatology (2019)

A woman in her early 80s presented with a 6-month history of an asymptomatic, enlarging, partly infiltrated erythematous cutaneous patch localized to the periareolar area of her left breast. What is your diagnosis?
NCMP-07. SECONDARY ADRENAL INSUFFICIENCY IN ADULT PATIENTS WITH GLIOMA: A CASE SERIES
Authors: Emmanuel Mantilla, Jessica Abramowitz, Tu Dan, Edward Pan
Journal: Neuro-Oncology (2019)

Abstract Glucocorticoids (GC) are a mainstay in the treatment of gliomas to reduce cerebral edema and improving symptoms related to swelling. Prolonged GC use can lead to adrenal insufficiency (AI) due to the suppression of the hypothalamic-pituitary-adrenal axis. AI is challenging to diagnose as the tumor itself or the chemotherapy are blamed for the symptoms. This study aims to evaluate the risk factors predisposing patients with gliomas to develop AI during their treatment course. METHODS This is a retrospective case review. Charts in the neuro-oncology clinic from July 2018 to March 2018 were reviewed. Inclusion criteria include &gt; 18 y/o, diagnosis of glioma WHO Grade II to IV, and diagnosis of secondary AI. Demographic profile, tumor characteristics, radiation dose, exposure or proximity to HPA, current treatment, and dexamethasone dose and duration of treatment were tabulated and compared. RESULTS Nine of ten patients were started on high dose of dexamethasone (&gt; 8mg daily), and only one was started on a lower dose (&lt; 4mg daily). Majority of the patients (50%) were on dexamethasone for less than a year (4–8 months), and a significant portion (40%) of the patients remained on dexamethasone for &gt; 2 years, with one patient on steroids for 64 months. The minimum dose of dexamethasone needed to prevent symptoms ranged from 0.5mg to 2mg daily. Most received 60Gy of radiation, two received 59.4 Gy, and one received 54 Gy. Six patients had radiation exposure to the HP axis, while four didn’t. CONCLUSION Secondary adrenal insufficiency results from prolonged glucocorticoid use in patients with glioma. Dose and duration of GC are risk factors to its development. Radiation to the HPA axis may be a contributing factor to the development of AI in patients with glioma, although it can also be seen in patients with radiation distant from the HPA.
High Level Phosphatase Activity Revealed in Chronic Lymphocytic Leukemia Cells That Use Mutated Immunoglobulin Heavy Chain Variable Region Genes and Lack High-Level Expression of the Zeta-Associated Protein 70 (ZAP-70).
Authors: Wendy J. Fantl, Rolla L. Yafawi, Santosh K. Putta, Ying-Wen Huang, Helen L. Francis-Lang, Rassenti Z. Laura, Aileen Cleary Cohen, Thomas J. Kipps
Journal: Blood (2007)
Dangerous Anaesthetic Device
Authors: R. E. W. Manley
Journal: BMJ (1964)

lower incidence of cervical carcinoma prob- ably was related to the universal practice of male circumcision amongst the Muslim com- munity.That male circumcision is unlikely to be the only factor involved in reducing cervical carcinoma is evident from the con- flicting literature on the subject.As Elliott3 points out, " No more can be said for the argument than that it is a hypothesis which fits the facts."As such it deserves consideration.-I am, etc.,
Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study
Authors: Sasanka M. Handunnetti, Amit Khot, Mary Ann Anderson, Piers Blombery, Kate Burbury, David Ritchie, Rodney J. Hicks, Besiat Birbirsa, Mathias Bressel, Juliana Di Iulio, David Alan Westerman, Stephen Lade, Andrew W. Roberts, John F. Seymour, Constantine S. Tam
Journal: Blood (2019)
INNV-27. THE IMPACT OF A DEDICATED MULTIDISCIPLINARY TUMOR BOARD ON CARE FOR PATIENTS WITH BRAIN METASTASES
Authors: Nancy Wang, Justine Cohen, Nathaniel Goss, Mia Bertalan, Maura Keeley, Michael Parsons, Brian Nahed, Daniel Cahill, Kevin Oh, Priscilla Brastianos
Journal: Neuro-Oncology (2019)

Abstract Brain metastases (BM) are the most common tumors to affect the central nervous system (CNS). Treatment options have recently evolved with the use of new targeted therapies, immune checkpoint inhibitors, and increased access to clinical trials. We describe our institutional experience with a weekly tumor board dedicated to BM. METHODS We conducted a single-institution cohort study at an academic hospital. Attendance at tumor board included representatives from neuro-oncology, medical oncology, radiation oncology, neurosurgery, neuropsychology, and neuroradiology. We prospectively gathered data on patient demographics, clinical history, and tumor board recommendations. Patients were followed to assess treatment course and survival. The Kaplan Meier method was used to calculate time to progression. RESULTS A total of 49 patients were presented over 2 months. The median age at presentation was 63 yrs with a median ECOG of 1. The primary malignancy was 35% melanoma, 29% lung, 23% breast, the remainder other. Most patients had advanced, heavily pretreated disease: 69% had Stage IV disease with a median of 2 prior lines of systemic therapy, 73% had multiple BM, 39% had prior surgical resection of BM, and 57% had prior CNS radiation. Change in management was recommended in 26/53 case presentations, with active BM-directed therapy (surgery, radiation, systemic therapy) recommended in 25/26 patients. The median time to start active therapy was 7 days. Only 3 patients have died at a median follow-up of 62 days. 9 patients have progressed, with a median time to progression of 57 days. CONCLUSIONS Multidisciplinary BM tumor board provides unique opportunities in the management of complex BM patients in an era of rapidly evolving therapeutic options. Additional follow-up is needed to assess long-term outcomes.
Measles seroprevalence in pregnant women in Soweto, South Africa: a nested cohort study
Authors: N.C. Gieles, E.A.M.L. Mutsaerts, G. Kwatra, L. Bont, C.L. Cutland, S. Jones, A. Moultrie, S.A. Madhi, M.C. Nunes
Journal: Clinical Microbiology and Infection (2019)

Measles infection causes particularly severe disease in young children who, prior to vaccination, are dependent on maternal antibodies for protection against infection. Measles vaccination was introduced into the South African public immunization programme in 1983 and became widely available in 1992. The aim of this study was to determine measles-specific immunoglobulin G (IgG) levels in pregnant women living with and without HIV born before and after measles vaccine introduction in South Africa.Measles IgG antibody level from blood obtained at the time of delivery was compared between women who were born before 1983 (n = 349) and since 1992 (n = 349). Serum samples were tested for measles IgG antibody using an enzyme-linked immunosorbent assay. Geometric mean titres (GMTs) and the proportion with seronegative (<200 mIU/mL) or seropositive titres (≥275 mIU/mL) were compared.Women born since 1992 had lower GMTs [379.7 mIU/mL (95% CI 352.7-448.6)] and fewer were seropositive (55.9%, 195/349) than women born before 1983 [905.8 mIU/mL (95% CI 784.7-1045.5); 76.8%, 268/349], for both comparisons p < 0.001.We found an association between measles vaccine implementation into the public immunization program in South Africa and peri-partum maternal measles immunity, where women born before vaccine introduction had higher measles IgG antibody titres and were more likely to be seropositive. These findings suggest a need to reconsider the infant measles immunization schedule in settings where women have derived immunity mainly from measles vaccine rather than wild-type virus exposure.
The "Sterilization" of Endoscopic Instruments
Authors: Peter Dineen
Journal: JAMA (1961)

A new method was sought for sterilizing endoscopic instruments. Formaldehyde cabinets are unsatisfactory. Endoscopic instruments do not tolerate autoclaving. A new method of sterilizing by moist heat has been used in the laboratory and shown to be an improvement. It involves immersing the contaminated instrument in a waterbath at 85° C. for one hour. This has become possible since the development of a more heat-resistant cement. In the experiments here reported the method killed most pathogenic organisms, including<i>Mycobacterium tuberculosis, Staphylococcus aureus, Escherichia coli, Proteus vulgaris</i>, and<i>Pseudomonas pyocyaneus</i>. Enterococci were not uniformly eliminated by this method.
Genome-Wide Methylation Analysis Using the Digital Restriction Enzyme Analysis of Methylation for Stratification of Patients with Juvenile Myelomonocytic Leukemia
Authors: Hironobu Kitazawa, Hideki Muramatsu, Norihiro Murakami, Yusuke Okuno, Manabu Wakamatsu, Taro Yoshida, Masayuki Imaya, Ayako Yamamori, Shunsuke Miwata, Kotaro Narita, Motoharu Hamada, Daisuke Ichikawa, Rieko Taniguchi, Nozomu Kawashima, Eri Nishikawa, Atsushi Narita, Nobuhiro Nishio, Seiji Kojima, Yoshiyuki Takahashi
Journal: Blood (2019)
The lipid-droplet-associated protein ABHD5 protects the heart through proteolysis of HDAC4
Authors: Zegeye H. Jebessa, Kumar D. Shanmukha, Matthias Dewenter, Lorenz H. Lehmann, Chang Xu, Friederike Schreiter, Dominik Siede, Xue-Min Gong, Barbara C. Worst, Giuseppina Federico, Sven W. Sauer, Tamas Fischer, Lisa Wechselberger, Oliver J. Müller, Samuel Sossalla, Christoph Dieterich, Patrick Most, Herrmann-Josef Gröne, Cedric Moro, Monika Oberer, Guenter Haemmerle, Hugo A. Katus, Jens Tyedmers, Johannes Backs
Journal: Nature Metabolism (2019)
A New Mechanism for T-ALL Leukemogenesis: Early Expression of Alpha-Beta TCR Occurs in a Natural Subset of CD4-CD8- Double Negative (DN) Thymocytes Where MHC Engagement May Drive NOTCH Mutation and Tumor Initiation
Authors: Kimberly G Laffey, Robert J Stiles, Melissa Ludescher, Tessa Davis, Shariq S Khwaja, Richard J. Bram, Peter J Wettstein, Venkataraman Ramachandran, Cory E Johnson, Richard Hammer, Chi-Ren Shyu, Diana Gil, Adam G Schrum
Journal: Blood (2019)